Helen Louise Collins, the Chief Medical Officer at Enliven Therapeutics, Inc., engaged in recent transactions involving the sale of common stock and the acquisition through option exercise. On May 18, 2026, Ms. Collins sold a total of 5,000 shares of the company's common stock for $198,971.
These sales were not isolated events; they occurred across multiple trades with varying prices, ranging from a low of $38.855 to a high of $41.605 per share. Specifically, the 5,000 shares sold represented three separate transactions executed at weighted average prices of $39.534, $40.2473, and $41.2052.
In a preceding action, Ms. Collins also increased her holdings by acquiring another 5,000 shares of common stock through the exercise of existing stock options. The entire series of transactions-both the sales and the acquisitions-was implemented following a Rule 10b5-1 trading plan that was initially adopted on October 19, 2025.
Current Holdings and Corporate Developments
Following these recent trades, Ms. Collins' direct ownership of Enliven Therapeutics common stock totals 25,000 shares. This figure incorporates certain restricted stock units (RSUs), which are defined as contingent rights to receive one share of the Issuer’s common stock. Furthermore, her total holdings include 126,268 derivative securities, representing remaining stock options.
Beyond executive activity, Enliven Therapeutics has been making announcements regarding its clinical pipeline. The company recently announced that updated data from its Phase 1 ENABLE trial for ELVN-001, which targets chronic myeloid leukemia (CML), is slated for presentation at the European Hematology Association Congress. This data provides key insights into treatment efficacy.
According to the reported findings, the initial Phase 1b cohort demonstrated a cumulative major molecular response rate of 47%. For this group, a further 38% of patients achieved this favorable response by the 24-week mark. When comparing outcomes in patients who had previously received asciminib, the cumulative response rate was noted at 52%.
Analyst Coverage and Market Sentiment
The company's lead drug candidate is attracting significant attention from market analysts, suggesting growing institutional interest and confidence. Several firms have reiterated or initiated coverage with positive outlooks and price targets.
-
Risks
- Stock volatility, evidenced by a recent 7.8% decline over the past week.
- Analyst assessment suggesting the stock may be overvalued at current levels (InvestingPro analysis).
- The reliance on future clinical data presentations and competitive market outcomes.
More from Insider Trading